Cardiovascular disease: risk assessment and reduction, including lipid modification

assessing response to treatment. Lipid target for people taking statins 1.6.1 For primary prevention of CVD aim for a greater than 40% reduction in non-HDL cholesterol. [May 2023] Optimising lifestyle changes 1.6.2 Before offering statin treatment for primary prevention, discuss the benefits of lifestyle changes and optimise the management of all other modifiable CVD risk factors if possible. [May 2023] 1.6.3 Recognise that people may need support to change their lifestyle. To help them do this, refer them to programmes such as exercise referral schemes or weight management services. (See NICE's guidelines on behaviour change: individual approaches, physical activity: exercise referral schemes and overweight and obesity management.) [May 2023] 1.6.4 Offer people the opportunity to have their risk of CVD assessed again after they have tried to change their lifestyle. [May 2023] 1.6.5 If lifestyle change is ineffective or inappropriate offer statin treatment. [May 2023] Treating comorbidities and secondary causes of dyslipidaemia 1.6.6 Before starting statins, treat comorbidities and secondary causes of dyslipidaemia. [May 2023] Statin treatment for people with and without type 2 diabetes 1.6.7 Offer atorvastatin 20 mg for the primary prevention of CVD to people who have a 10-year QRISK3 score of 10% or more. [May 2023]
